D&A
Elevance Health D&A decreased by 12.8% to $354.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 5.1%, from $373.00M to $354.00M. Over 4 years (FY 2021 to FY 2025), D&A shows an upward trend with a 4.4% CAGR.
Analysis
How to read this metric
Higher levels indicate significant capital investment in infrastructure or acquisitions, while lower levels may suggest aging assets or limited capital expenditure.
Detailed definition
This represents the non-cash expense allocated to the cost of tangible and intangible assets over their useful lives. Be...
Peer comparison
High in capital-intensive industries like manufacturing and healthcare devices; lower in service-based sectors.
depreciation_and_amortization_cfHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $309.00M | $351.00M | $360.00M | $358.00M | $393.00M | $451.00M | $473.00M | $462.00M | $433.00M | $426.00M | $424.00M | $331.00M | $335.00M | $329.00M | $398.00M | $373.00M | $380.00M | $387.00M | $406.00M | $354.00M |
| QoQ Change | — | +13.6% | +2.6% | -0.6% | +9.8% | +14.8% | +4.9% | -2.3% | -6.3% | -1.6% | -0.5% | -21.9% | +1.2% | -1.8% | +21.0% | -6.3% | +1.9% | +1.8% | +4.9% | -12.8% |
| YoY Change | — | — | — | — | +27.2% | +28.5% | +31.4% | +29.1% | +10.2% | -5.5% | -10.4% | -28.4% | -22.6% | -22.8% | -6.1% | +12.7% | +13.4% | +17.6% | +2.0% | -5.1% |
Business Segments
| Segment | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q2 '24 | Q3 '24 |
|---|---|---|---|---|---|---|---|---|
| Corporate & Other | — | — | — | $221.00M | $220.00M | — | $234.00M | $231.00M |
| Carelon Services | — | — | — | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Carelon Services Segment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Carelon Total | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — | — |
| CarelonRx | — | — | — | $0.00 | $0.00 | — | $0.00 | $0.00 |
| CarelonRx Segment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Corporate & Other Segment | $196.00M | $196.00M | $218.00M | $218.00M | $218.00M | $218.00M | — | — |
| Health Benefits | — | — | — | $0.00 | $0.00 | — | $0.00 | $0.00 |
| Health Benefits Segment | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Segment Eliminations | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | — |
| Total | $451.00M | $473.00M | $462.00M | $433.00M | $426.00M | $424.00M | $335.00M | $329.00M |
Carelon Services Segment, Carelon Total, CarelonRx Segment, Corporate & Other Segment, Health Benefits Segment, Segment Eliminations are derived from annual filings.
Carelon Services, Carelon Services Segment, CarelonRx, CarelonRx Segment, Corporate & Other, Corporate & Other Segment, Health Benefits, Health Benefits Segment, Segment Eliminations were previously reported and have since been discontinued or reclassified. Only currently active segments are shown in the chart.
D&A at Other Companies
Frequently Asked Questions
- What is Elevance Health's d&a?
- Elevance Health (ELV) reported d&a of $354.00M in Q1 2026.
- How has Elevance Health's d&a changed year-over-year?
- Elevance Health's d&a decreased by 5.1% year-over-year, from $373.00M to $354.00M.
- What is the long-term trend for Elevance Health's d&a?
- Over 4 years (2021 to 2025), Elevance Health's d&a has grown at a 4.4% compound annual growth rate (CAGR), from $1.30B to $1.55B.
- What does d&a mean?
- The non-cash accounting expense for the wear and tear or expiration of assets.